Navigation Links
Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women

SAN JOSE, Calif., May 23, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, announced today the publication of a study that provides more information on the factors which may influence the amount of fetal DNA found in maternal blood. The study was led by Professor Kypros Nicolaides, MD, of Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in the United Kingdom.

(Logo: )

The study demonstrated that fetal DNA amounts did not differ significantly between pregnant women who have Trisomy 21 fetuses (associated with Down syndrome) and those who have euploid fetuses (no trisomy). Maternal weight and serum screening markers were found to correlate with fetal DNA amounts suggesting that placental size relative to the mother is the major factor influencing fetal DNA concentration in maternal blood. The study, which will be published in a future print edition of Fetal Diagnosis & Therapy, is available now online at

"The ability to detect Trisomy 21 with cell-free DNA is dependent upon assay precision and fetal fraction in the sample rather than upon the prevalence of disease in the study population," stated Professor Nicolaides. "While further studies are warranted, our results suggest that cell free DNA testing may be applicable in both high and low risk pregnancies."

"We are committed to advancing science and research in the field of non-invasive prenatal testing," said Ken Song, chief executive officer at Ariosa Diagnostics. "It is important that clinical data and scientific principles take center stage as non-invasive tests, such as the Harmony™ Prenatal Test, are used by healthcare providers to manage pregnant women. This additional research into the presence of fetal DNA in maternal blood will help us to better identify which patients may be appropriate for prenatal testing."

Ariosa Diagnostics developed the Harmony Prenatal Test, which is currently available in selected US locations and will be broadly available in June. The Harmony Prenatal Test is performed using a simple maternal blood draw and detects fetal trisomy via analysis of cell-free DNA in maternal blood.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit

SOURCE Ariosa Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ariosa Diagnostics Announces Nationwide Launch of the Harmony™ Prenatal Test Through LabCorp
2. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
3. Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrigs Disease)
4. Nanoscale magnetic media diagnostics by rippling spin waves
5. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
6. Berg Diagnostics Receives CLIA Certification and Launches Novel Vitamin D Assay
7. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
8. The butterfly effect in nanotech medical diagnostics
9. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
10. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
11. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ... Dr. Norman C.W. Wong to its Board of ... comes to Zenith with a wealth of experience as co-founder ... molecular biology. --> --> ... Zenith Epigenetics, board of directors. Zenith,s long standing expertise in ...
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015 ... today that the company has acquired Cypher Genomics, Inc., ... and robust human genomic interpretation software solutions. The ... who will join HLI including Cypher CEO and Co-founder, ... head of HLI,s Pediatric Business.  Financial details of the ...
(Date:11/30/2015)... 2015  AbbVie, is introducing Good Morning Hypothyroidism ... daily routine for managing the life-long condition of hypothyroidism. ... the way the body absorbs it so resources encouraging ... routine are important. The goal of the new website ... their hypothyroidism by establishing a daily routine, spirit of ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... has been awarded an additional grant of approximately $735,000 from ... (OCS). This grant, the second this year, brings the total ... $1.8 million (approximately NIS7 million).  ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
Breaking Biology News(10 mins):